menu

CME: New Systemic Options for Managing cSCC: A Care Team Forum

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

New Systemic Options for Managing cSCC: A Care Team Forum

close
New Systemic Options for Managing cSCC: A Care Team Forum
Restart
Resume
Read full article
Choose a format
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    Please note:This activity is no longer available for continuing education credit. 

    This is the first of a 2-part round-table discussion that brings together the expertise of a dermatologist, medical oncologist, and Mohs surgeon and pairs it with a first-hand account of how Jim, a cutaneous squamous cell carcinoma (cSCC) survivor, and his caregiver navigated the ups and downs of a rapidly-metastatic cSCC diagnosis and treatment labyrinth. In this activity, learners will explore pressing questions regarding the safety and efficacy of new systemic options for managing advanced cSCC not otherwise amenable to curative surgical strategies.

  • Disclosure Declaration

    It is the policy of RMEI Medical Education, LLC and AKH Inc., Advancing Knowledge in Healthcare, to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by RMEI and AKH prior to accreditation of the activity and may include any of, or a combination of, the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence supports the recommendation; moderator review; and peer review.

    AKH planners and reviewers have no relevant financial relationships to disclose.

    • Chrysalyne D. Schmults, MD, MSCE, has affiliations with Genentech, Novartis, Regeneron Pharmaceuticals (Consulting); Castle Biologics project in CsCC prognostics (Steering Committee Member).
    • Omid Hamid, MD, has affiliations with Amgen, Array, BMS, Genentech/Roche, Novartis, Sanofi (Speakers Bureau); Amgen, BMS, Genentech/Roche, Merck, Novartis (Consulting); AstraZeneca, BMS, Celldex, Genentech/Roche, Immunocore, Incyte, MedImmune Novartis, Merck, Merck Serono, Pfizer, Rinat (Contracted Research for Institution).
    • Anokhi Jambusaria, MD, MSCE, FAAD, has affiliations with Regeneron (Consulting).

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    RMEI Medical Education, LLC

    • Lobna Eldasher, PharmD, has no affiliations with commercial interests to disclose.
    • Sharon Powell, has no affiliations with commercial interests to disclose.

    AKH Staff And Planners

    • Dorothy Caputo, MA, BSN, RN, Director of Accreditation, Planner, has no
    • affiliations with commercial interests to disclose.
    • Patricia Brignoni, AKH Sr. Project Manager, has no affiliations with commercial interests to disclose.

    DISCLOSURE OF UNLABELED USE

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. 

    Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Target Audience

    The intended audience for this activity is Mohs surgeons, medical oncologists, and dermatologists who manage patients with cSCC.

  • Learning Objectives

    Upon successful completion of this activity, participants should be better able to:

    • Utilize novel and emerging agents to manage advanced cSCC based on their efficacy and safety data and mechanisms of action
    • Incorporate shared decision making (SDM), quality of life assessment and management, and collaborative care for patients with cSCC to improve patient outcomes
  • Continuing Education Information

    Physicians

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

    AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Physician Assistants

    The National Commission on Certification of Physician Assistants (NCCPA) accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

  • Providers

    Jointly provided by RMEI Medical Education, LLC and AKH Inc., Advancing Knowledge in Healthcare.

  • Commercial Support

    This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

  • How to Receive Credit

    By reviewing the course content and successfully completing the post-test and evaluation, physicians and PAs are entitled to receive up to 0.5 AMA PRA Category 1 Credit(s)™ and nurses are entitled to receive up to 0.5 contact hour. A statement of credit will be available to print from your user history page. Users must:

    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the activity post-test and evaluation.

    Physicians and PAs who successfully complete the post-test and evaluation will receive CME/CE credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

  • Publication Dates

    Release Date:

    Expiration Date: This activity is no longer available for continuing education credit. 

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Please note:This activity is no longer available for continuing education credit. 

    This is the first of a 2-part round-table discussion that brings together the expertise of a dermatologist, medical oncologist, and Mohs surgeon and pairs it with a first-hand account of how Jim, a cutaneous squamous cell carcinoma (cSCC) survivor, and his caregiver navigated the ups and downs of a rapidly-metastatic cSCC diagnosis and treatment labyrinth. In this activity, learners will explore pressing questions regarding the safety and efficacy of new systemic options for managing advanced cSCC not otherwise amenable to curative surgical strategies.

  • Disclosure Declaration

    It is the policy of RMEI Medical Education, LLC and AKH Inc., Advancing Knowledge in Healthcare, to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by RMEI and AKH prior to accreditation of the activity and may include any of, or a combination of, the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence supports the recommendation; moderator review; and peer review.

    AKH planners and reviewers have no relevant financial relationships to disclose.

    • Chrysalyne D. Schmults, MD, MSCE, has affiliations with Genentech, Novartis, Regeneron Pharmaceuticals (Consulting); Castle Biologics project in CsCC prognostics (Steering Committee Member).
    • Omid Hamid, MD, has affiliations with Amgen, Array, BMS, Genentech/Roche, Novartis, Sanofi (Speakers Bureau); Amgen, BMS, Genentech/Roche, Merck, Novartis (Consulting); AstraZeneca, BMS, Celldex, Genentech/Roche, Immunocore, Incyte, MedImmune Novartis, Merck, Merck Serono, Pfizer, Rinat (Contracted Research for Institution).
    • Anokhi Jambusaria, MD, MSCE, FAAD, has affiliations with Regeneron (Consulting).

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    RMEI Medical Education, LLC

    • Lobna Eldasher, PharmD, has no affiliations with commercial interests to disclose.
    • Sharon Powell, has no affiliations with commercial interests to disclose.

    AKH Staff And Planners

    • Dorothy Caputo, MA, BSN, RN, Director of Accreditation, Planner, has no
    • affiliations with commercial interests to disclose.
    • Patricia Brignoni, AKH Sr. Project Manager, has no affiliations with commercial interests to disclose.

    DISCLOSURE OF UNLABELED USE

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. 

    Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Target Audience

    The intended audience for this activity is Mohs surgeons, medical oncologists, and dermatologists who manage patients with cSCC.

  • Learning Objectives

    Upon successful completion of this activity, participants should be better able to:

    • Utilize novel and emerging agents to manage advanced cSCC based on their efficacy and safety data and mechanisms of action
    • Incorporate shared decision making (SDM), quality of life assessment and management, and collaborative care for patients with cSCC to improve patient outcomes
  • Continuing Education Information

    Physicians

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

    AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Physician Assistants

    The National Commission on Certification of Physician Assistants (NCCPA) accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

  • Providers

    Jointly provided by RMEI Medical Education, LLC and AKH Inc., Advancing Knowledge in Healthcare.

  • Commercial Support

    This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

  • How to Receive Credit

    By reviewing the course content and successfully completing the post-test and evaluation, physicians and PAs are entitled to receive up to 0.5 AMA PRA Category 1 Credit(s)™ and nurses are entitled to receive up to 0.5 contact hour. A statement of credit will be available to print from your user history page. Users must:

    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the activity post-test and evaluation.

    Physicians and PAs who successfully complete the post-test and evaluation will receive CME/CE credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

  • Publication Dates

    Release Date:

    Expiration Date: This activity is no longer available for continuing education credit. 

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 12/3/20